Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer
Authors
Keywords
Tmem173, Immune checkpoint inhibitors, Safety, Chemotherapy, Synergy
Journal
CANCER LETTERS
Volume 500, Issue -, Pages 163-171
Publisher
Elsevier BV
Online
2020-12-03
DOI
10.1016/j.canlet.2020.11.049
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
- (2020) Carminia M. Della Corte et al. Journal of Thoracic Oncology
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
- (2019) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- cGAS/STING axis mediates a topoisomerase II inhibitor–induced tumor immunogenicity
- (2019) Zining Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- STING: a master regulator in the cancer-immunity cycle
- (2019) Yuanyuan Zhu et al. Molecular Cancer
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- (2019) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
- (2018) Dewan Md Sakib Hossain et al. JOURNAL OF CLINICAL INVESTIGATION
- Can innate immune system targets turn up the heat on 'cold' tumours?
- (2018) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of Advanced Non–Small Cell Lung Cancer in 2018
- (2018) Deborah B. Doroshow et al. JAMA Oncology
- Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses
- (2018) Rafael Cubas et al. JOURNAL OF IMMUNOLOGY
- Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
- (2018) Gillian Dunphy et al. MOLECULAR CELL
- LBA54IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)
- (2018) F Barlesi et al. ANNALS OF ONCOLOGY
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
- (2018) Shannon Grabosch et al. ONCOGENE
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- Danger signals: Chemotherapy enhancers?
- (2017) Thaiz Rivera Vargas et al. IMMUNOLOGICAL REVIEWS
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
- (2017) Lee Pai‐Scherf et al. ONCOLOGIST
- cGAS is essential for the antitumor effect of immune checkpoint blockade
- (2017) Hua Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
- (2017) Jeremy B. Foote et al. Cancer Immunology Research
- Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
- (2016) E. Beyranvand Nejad et al. CANCER RESEARCH
- Diminished but not dead: chemotherapy for the treatment of NSCLC
- (2016) Roy S Herbst et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. ONCOLOGIST
- Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
- (2016) Yu Zhang et al. JAMA Oncology
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- The STING pathway and the T cell-inflamed tumor microenvironment
- (2015) Seng-Ryong Woo et al. TRENDS IN IMMUNOLOGY
- Acquired and intrinsic resistance in cancer immunotherapy
- (2014) Sander Kelderman et al. Molecular Oncology
- Cyclic Dinucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune Signaling
- (2013) Hiroyasu Konno et al. CELL
- STING-dependent cytosolic DNA sensing pathways
- (2013) Glen N. Barber TRENDS IN IMMUNOLOGY
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
- (2012) L. Sun et al. SCIENCE
- Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
- (2011) S. R. Mattarollo et al. CANCER RESEARCH
- CXCR3 in T cell function
- (2011) Joanna R. Groom et al. EXPERIMENTAL CELL RESEARCH
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
- (2009) Hiroki Ishikawa et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started